Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma

Blood

Volumn 87, Issue 11, 1996, Pages 4718-4722

  Eitzman, Daniel T ^a   Krauss, John C ^a   Shen, Tingliang ^a   Cui, Jisong ^a   Ginsburg, David ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; HOST RESISTANCE; INHIBITION KINETICS; LUNG METASTASIS; MELANOMA; MEMBRANE DAMAGE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSGENIC MOUSE;

ANIMALS; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; TRANSGENES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029956043     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139, 1985
2. Vassalli J-D, Pepper MS: Membrane proteases in focus. Nature 370:14, 1994
3. Cajot JF, Kruithof EK, Schleuning WD, Sordat B, Bachmann F: Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 38:719, 1986
4. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48:1270, 1988
5. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K, Grndahl-Hansen J, Dan K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138:1059, 1991
6. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47:487, 1986
7. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J Cell Biol 107:2437, 1988
8. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90:5021, 1993
9. Sordat B, Reiter L, Cajot J-F: Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type 1 plasminogen activator inhibitor. Cell Diff Devel 32:277, 1990
10. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611, 1983
11. Ossowski L: Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52:321, 1988
12. Lawrence DA, Ginsburg D: Plasminogen activator inhibitors, in High KA, Roberts HR (eds): Molecular Basis of Thrombosis and Hemostasis. New York, NY Marcel Dekker, 1995, p 517
13. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729, 1992
14. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D: Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756, 1993
15. Hamsten A, Wiman B, de Faire U, Blombäck M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557, 1985
16. Wiman B, Hamsten A: The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 16:207, 1990
17. Ellis V, Wun T-C, Behrendt N, Ronne E, Dano K: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265:9904, 1990
18. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL, Testuz J, Sordat B: Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87:6939, 1990
19. Poggi A, Bellelli E, Castelli MP, Marinacci R, Rella C, Erickson LA, Donati MB, Bini A: Reduced Lewis lung carcinoma (3LL) metastases in mice transgenic for human plasminogen activator inhibitor-1 (PAI-1). Proc Annu Meet Am Assoc Cancer Res 34:A430, 1993 (abstr)
20. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92:205, 1995
21. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K: The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51:4067, 1991
22. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A: Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasis. Thromb Res 63:59, 1991
23. Shirasuna K, Saka M, Hayashido Y, Yoshioka H, Sugiura T, Matsuya T: Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res 53:147, 1993
24. Gris JC, Schved JF, Marty-Double C, Mauboussin JM, Balmes P: Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 104:8, 1993
25. Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EK, Lijnen HR, Burtin P: The plasminogen-activation system in ovarian tumors. Int J Cancer 55:27, 1993
26. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC: Plasminogen activator inhibitor-1 gene-deficient mice. 1. Generation by homologous recombination and characterization. J Clin Invest 92:2746, 1993
27. Prendergast GC, Diamond LE, Dahl D, Cole MD: The c-myc-regulated gene mrl encodes plasminogen activator inhibitor I. Mol Cell Biol 10:1265, 1990
28. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D: Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95:2416, 1995
29. Krauss JC, Strome SE, Chang AE, Shu S: Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. Immunother 16:77, 1994
30. Plow EF, Freaney DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 103:2411, 1986
31. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O: Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer 48:481, 1991
32. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Post-lethwaite AE, Kang AH, Moses HL: Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 263:3111, 1988
33. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380, 1994